Clinical experience with a bronchospasmolytic aerosol combination.
A comparative study with different bronchospasmolytic inhalers (fenoterol, ipratropium bromide, combination IK-6) was done with ten patients with obstructive airway disease. After a delayed initial effect (owing to the propellant gas) ipratropium bromide showed a bronchospasmolytic effect as good as fenoterol, but without circulatory side effects. The combination with low dosed fenoterol (Berodual) produced equally good subjective and objective results with less side effects than the high dosed fenoterol. These results should form the basis for an optimal long term treatment.
D000328:Adult; D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D005280:Fenoterol / Q000627:therapeutic use; D005541:Forced Expiratory Volume; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008875:Middle Aged
D000336:Aerosols; D001993:Bronchodilator Agents; D004338:Drug Combinations; C030809:fenoterol, ipratropium drug combination; D005280:Fenoterol; D009241:Ipratropium